Production schedule Update

ADVANCE PURCHASE AGREEMENT FOR THE PRODUCTION, PURCHASE AND SUPPLY OF A COVID-19 VACCINE (AZD1222) IN THE EUROPEAN UNION

Strictly Confidential

4 Dec 2020



AZ Attendees

Name	Role
5.1.2e	5.1.2e

Production planning AZD1222 for European countries first trimester 2021



The indicated numbers are the currently estimated lower and upper bounds of the **CUMULATIVE number of doses** that AZ plans to deliver to all European markets in monthly deliveries in equal time frames.

<u>The Final Delivery Schedule is subject to:</u>

1. Regulatory Approval
2. Manufacturing yield
3. Final batch release timing including OMCL
4. Operationalising new EMA requirement for batch number stickers for each pack.

Key points

- Over the past half year AZ has **contractually secured the capacity of 300 million doses** for the EC and Member States
- **Production has started** and first final product batches will be ready for release upon approval beginning of 2021
- **Timing of regulatory approval** now assumed for early 2021
- **Manufacturing process has been optimised** to improve the process yield, leading 5.1.1c in the phasing of the supply volumes during 2021. Given the currently assumed timing for EMA approval, this will have a **positive outcome on remaining shelf life**
- AZ will accommodate the request from the EC and Member States to **deliver on a monthly basis lower quantities of doses than the contractually agreed batch size, in order to assure simultaneous access by all Member States**
- AstraZeneca and its partners will continue it's tireless efforts **to maximize supply and to accelerate timing of our vaccine supply whilst maintaining our high quality standards**

Questions & answers

Back Up - Regulatory & Release Process Update

Standard Regulatory & Release Process




5.1.1c